Kerrisdale Advisers LLC Makes New $1.75 Million Investment in Establishment Labs Holdings Inc. $ESTA

Kerrisdale Advisers LLC acquired a new position in shares of Establishment Labs Holdings Inc. (NASDAQ:ESTA) during the second quarter, HoldingsChannel reports. The fund acquired 20,390 shares of the company’s stock, valued at approximately $1,750,000.

Several other hedge funds have also modified their holdings of ESTA. KBC Group NV bought a new position in Establishment Labs in the 1st quarter worth approximately $28,000. Quarry LP bought a new stake in shares of Establishment Labs during the third quarter worth $34,000. Northwestern Mutual Wealth Management Co. acquired a new position in shares of Establishment Labs during the second quarter valued at $43,000. Kestra Advisory Services LLC acquired a new position in shares of Establishment Labs during the fourth quarter valued at $47,000. Finally, Osaic Holdings Inc. boosted its holdings in Establishment Labs by 900.0% in the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock valued at $85,000 after acquiring an additional 1,800 shares during the last quarter. 72.91% of the stock is owned by institutional investors.

Establishment Labs Price Performance

Shares of ESTA stock opened at $70.64 on Monday. The company has a quick ratio of 2.52, a current ratio of 3.84 and a debt-to-equity ratio of 12.11. Establishment Labs Holdings Inc. has a 12-month low of $36.53 and a 12-month high of $97.59. The firm has a fifty day moving average of $85.00 and a 200-day moving average of $74.94. The firm has a market capitalization of $2.11 billion, a price-to-earnings ratio of -53.92 and a beta of 1.07.

Establishment Labs (NASDAQ:ESTA) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.05). Establishment Labs had a negative return on equity of 196.69% and a negative net margin of 15.82%.The business had revenue of $67.54 million for the quarter, compared to analyst estimates of $65.79 million. During the same period in the previous year, the business posted ($0.57) EPS. The business’s quarterly revenue was up 31.7% compared to the same quarter last year. On average, equities research analysts forecast that Establishment Labs Holdings Inc. will post -1.15 earnings per share for the current year.

Analyst Upgrades and Downgrades

ESTA has been the subject of several recent research reports. Mizuho boosted their price objective on Establishment Labs from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Wednesday, July 15th. Citigroup upgraded shares of Establishment Labs from a “neutral” rating to a “buy” rating and set a $92.00 price target for the company in a research report on Thursday, August 13th. JPMorgan Chase & Co. increased their price objective on shares of Establishment Labs from $84.00 to $95.00 and gave the company an “overweight” rating in a report on Friday, August 7th. BTIG Research lifted their target price on shares of Establishment Labs from $96.00 to $103.00 and gave the stock a “buy” rating in a report on Thursday, August 6th. Finally, Canaccord Genuity Group set a $105.00 target price on shares of Establishment Labs in a research report on Thursday, August 6th. Eight equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $100.25.

Establishment Labs Profile

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.